Date: 2016-07-28
Type of information: Development agreement
Compound: early stage hematology product candidates including a recombinant pegaspargase product candidate
Company: Jazz Pharmaceuticals (Ireland) Pfenex (USA - CA)
Therapeutic area: Hematologic diseases - Genetic diseases - Rare diseases
Type agreement: development commercialisation
Action mechanism:
Disease:
Details: * On July 28, 2016, Jazz Pharmaceuticals and Pfenex announced an agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates. The agreement also includes an option for Jazz Pharmaceuticals to negotiate a license for a recombinant pegaspargase product candidate with Pfenex. This early development stage collaboration demonstrates Jazz Pharmaceuticals' focus on identifying innovative technologies that may lead to the development of important therapeutic options for patients with hematological malignancies.
Under the agreement, Pfenex will receive upfront and option payments totaling $15 million and may be eligible to receive additional payments of up to $166 million based on the achievement of certain development-, regulatory-, and sales-related milestones, including up to $41 million for certain non-sales-related milestones. Pfenex may also be eligible to receive tiered royalties on worldwide sales of any products resulting from the collaboration. Both parties will be contributing to development efforts.
Financial terms:
Latest news:
